Denmark · Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 208.73 billion. The enterprise value is 228.72 billion.
| Market Cap | 208.73B |
| Enterprise Value | 228.72B |
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | Aug 25, 2026 |
Share Statistics
Novozymes has 465.91 million shares outstanding. The number of shares has increased by 63.49% in one year.
| Current Share Class | 412.17M |
| Shares Outstanding | 465.91M |
| Shares Change (YoY) | +63.49% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 34.07% |
| Float | 346.59M |
Valuation Ratios
The trailing PE ratio is 41.11 and the forward PE ratio is 25.52. Novozymes's PEG ratio is 3.01.
| PE Ratio | 41.11 |
| Forward PE | 25.52 |
| PS Ratio | 6.28 |
| PB Ratio | 2.45 |
| P/TBV Ratio | 164.14 |
| P/FCF Ratio | 37.27 |
| P/OCF Ratio | 22.38 |
| PEG Ratio | 3.01 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.46, with an EV/FCF ratio of 40.91.
| EV / Earnings | 44.20 |
| EV / Sales | 6.89 |
| EV / EBITDA | 18.46 |
| EV / EBIT | 29.64 |
| EV / FCF | 40.91 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.53 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.91 |
| Debt / FCF | 4.25 |
| Interest Coverage | 11.39 |
Financial Efficiency
Return on equity (ROE) is 6.21% and return on invested capital (ROIC) is 5.73%.
| Return on Equity (ROE) | 6.21% |
| Return on Assets (ROA) | 3.85% |
| Return on Invested Capital (ROIC) | 5.73% |
| Return on Capital Employed (ROCE) | 6.66% |
| Weighted Average Cost of Capital (WACC) | 7.17% |
| Revenue Per Employee | 2.94M |
| Profits Per Employee | 458,908 |
| Employee Count | 11,263 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.41 |
Taxes
In the past 12 months, Novozymes has paid 1.43 billion in taxes.
| Income Tax | 1.43B |
| Effective Tax Rate | 21.97% |
Stock Price Statistics
The stock price has increased by +8.26% in the last 52 weeks. The beta is 0.63, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +8.26% |
| 50-Day Moving Average | 443.86 |
| 200-Day Moving Average | 407.02 |
| Relative Strength Index (RSI) | 45.87 |
| Average Volume (20 Days) | 734,720 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 32.67 billion and earned 5.09 billion in profits. Earnings per share was 10.90.
| Revenue | 32.67B |
| Gross Profit | 18.40B |
| Operating Income | 7.63B |
| Pretax Income | 6.53B |
| Net Income | 5.09B |
| EBITDA | 12.23B |
| EBIT | 7.63B |
| Earnings Per Share (EPS) | 10.90 |
Balance Sheet
The company has 3.40 billion in cash and 23.39 billion in debt, with a net cash position of -19.99 billion or -42.91 per share.
| Cash & Cash Equivalents | 3.40B |
| Total Debt | 23.39B |
| Net Cash | -19.99B |
| Net Cash Per Share | -42.91 |
| Equity (Book Value) | 83.82B |
| Book Value Per Share | 179.29 |
| Working Capital | 5.87B |
Cash Flow
In the last 12 months, operating cash flow was 9.16 billion and capital expenditures -3.66 billion, giving a free cash flow of 5.50 billion.
| Operating Cash Flow | 9.16B |
| Capital Expenditures | -3.66B |
| Depreciation & Amortization | 4.60B |
| Net Borrowing | -280.32M |
| Free Cash Flow | 5.50B |
| FCF Per Share | 11.81 |
Margins
Gross margin is 56.32%, with operating and profit margins of 23.37% and 15.59%.
| Gross Margin | 56.32% |
| Operating Margin | 23.37% |
| Pretax Margin | 19.98% |
| Profit Margin | 15.59% |
| EBITDA Margin | 37.44% |
| EBIT Margin | 23.37% |
| FCF Margin | 16.84% |
Dividends & Yields
This stock pays an annual dividend of 6.50, which amounts to a dividend yield of 1.45%.
| Dividend Per Share | 6.50 |
| Dividend Yield | 1.45% |
| Dividend Growth (YoY) | 2.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 60.43% |
| FCF Payout Ratio | 55.88% |
| Buyback Yield | -63.49% |
| Shareholder Yield | -62.01% |
| Earnings Yield | 2.43% |
| FCF Yield | 2.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Novozymes is 509.33, which is 13.69% higher than the current price. The consensus rating is "Buy".
| Price Target | 509.33 |
| Price Target Difference | 13.69% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 7.59% |
| EPS Growth Forecast (3Y) | 9.55% |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 4.13 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.13 |
| Piotroski F-Score | 5 |